Article

Upcoming Live Broadcast to Feature Recent Data and Case Study in ALK+ Metastatic NSCLC

As the treatment landscape for ALK-positive metastatic non-small cell lung cancer continues to take shape, extended analyses of clinical trial data may offer additional clinical insight on the utility of approved therapies.

In an upcoming live broadcast, Alex Spira, MD, PhD, FACP, will share a case study in ALK-positive non-small cell lung cancer and discuss recent study findings for an available treatment option. Additionally, they will take questions and share clinical perspective through a live question and answer session.

To obtain clinical perspective and learn about how these results may impact your patients and your practice, watch the live broadcast on Wednesday, 5/26 at 6:00pm ET or 8:00pm ET; or on Wednesday, 6/16 at 12:00pm ET or 3:00pm ET. To register for the event, visit https://studio.mjhassoc.com/reach/takedaoncbroadcast.

USO-NON-02520 04/21

Related Videos
Steven H. Lin, MD, PhD
Haley M. Hill, PA-C, discusses the role of multidisciplinary management in NRG1-positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses preliminary data for zenocutuzumab in NRG1 fusion–positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses how physician assistants aid in treatment planning for NRG1-positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses DNA vs RNA sequencing for genetic testing in non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses current approaches and treatment challenges in NRG1-positive non–small cell lung cancer and pancreatic cancer.
Jessica Donington, MD, MSCR, Melina Elpi Marmarelis, MD, and Ibiayi Dagogo-Jack, MD, on the next steps for biomarker testing in NSCLC.
Jessica Donington, MD, MSCR, Melina Elpi Marmarelis, MD, and Ibiayi Dagogo-Jack, MD, on tissue and liquid biopsies for biomarker testing in NSCLC.
Jessica Donington, MD, MSCR, Melina Elpi Marmarelis, MD, and Ibiayi Dagogo-Jack, MD, on the benefits of in-house biomarker testing in NSCLC.
Jessica Donington, MD, MSCR, Melina Elpi Marmarelis, MD, and Ibiayi Dagogo-Jack, MD, on treatment planning after biomarker testing in NSCLC.